These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38828669)

  • 1. PD-L1 regulates tumor proliferation and T-cell function in NF2-associated meningiomas.
    Wang Y; Zhang C; Yan M; Ma X; Song L; Wang B; Li P; Liu P
    CNS Neurosci Ther; 2024 Jun; 30(6):e14784. PubMed ID: 38828669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic and local immunosuppression in patients with high-grade meningiomas.
    Li YD; Veliceasa D; Lamano JB; Lamano JB; Kaur G; Biyashev D; Horbinski CM; Kruser TJ; Bloch O
    Cancer Immunol Immunother; 2019 Jun; 68(6):999-1009. PubMed ID: 31030234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.
    Bush ML; Oblinger J; Brendel V; Santarelli G; Huang J; Akhmametyeva EM; Burns SS; Wheeler J; Davis J; Yates CW; Chaudhury AR; Kulp S; Chen CS; Chang LS; Welling DB; Jacob A
    Neuro Oncol; 2011 Sep; 13(9):983-99. PubMed ID: 21778190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors.
    Wang S; Liechty B; Patel S; Weber JS; Hollmann TJ; Snuderl M; Karajannis MA
    J Neurooncol; 2018 May; 138(1):183-190. PubMed ID: 29427150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoglycin promotes meningioma development through downregulation of NF2 and activation of mTOR signaling.
    Mei Y; Du Z; Hu C; Greenwald NF; Abedalthagafi M; Agar NYR; Dunn GP; Bi WL; Santagata S; Dunn IF
    Cell Commun Signal; 2017 Sep; 15(1):34. PubMed ID: 28923059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma.
    Han SJ; Reis G; Kohanbash G; Shrivastav S; Magill ST; Molinaro AM; McDermott MW; Theodosopoulos PV; Aghi MK; Berger MS; Butowski NA; Barani I; Phillips JJ; Perry A; Okada H
    J Neurooncol; 2016 Dec; 130(3):543-552. PubMed ID: 27624915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hsa_circ_0004872 mitigates proliferation, metastasis and immune escape of meningioma cells by suppressing PD-L1.
    Chen K; Huang Z; Liu C; Ouyang Q; Yan Q; Zheng W; Huang Y
    Metab Brain Dis; 2024 Jun; 39(5):895-907. PubMed ID: 38771413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas.
    Dickinson PJ; Surace EI; Cambell M; Higgins RJ; Leutenegger CM; Bollen AW; LeCouteur RA; Gutmann DH
    Vet Pathol; 2009 Sep; 46(5):884-92. PubMed ID: 19429976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.
    Beauchamp RL; Erdin S; Witt L; Jordan JT; Plotkin SR; Gusella JF; Ramesh V
    J Biol Chem; 2021; 296():100157. PubMed ID: 33273014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.
    Angus SP; Oblinger JL; Stuhlmiller TJ; DeSouza PA; Beauchamp RL; Witt L; Chen X; Jordan JT; Gilbert TSK; Stemmer-Rachamimov A; Gusella JF; Plotkin SR; Haggarty SJ; Chang LS; Johnson GL; Ramesh V;
    Neuro Oncol; 2018 Aug; 20(9):1185-1196. PubMed ID: 29982664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of the status of immune checkpoint molecules (PD-L1 and PD-1) in meningiomas by immunohistochemistry.
    Saygin İ; Çakir E; Kazaz SN; Güvercin AR; Eyüpoğlu İ; Ustaoğlu MM
    Turk J Med Sci; 2024; 54(4):735-743. PubMed ID: 39295608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.
    Kalamarides M; Stemmer-Rachamimov AO; Takahashi M; Han ZY; Chareyre F; Niwa-Kawakita M; Black PM; Carroll RS; Giovannini M
    Brain Pathol; 2008 Jan; 18(1):62-70. PubMed ID: 17924978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas.
    Hao S; Huang G; Feng J; Li D; Wang K; Wang L; Wu Z; Wan H; Zhang L; Zhang J
    J Neurooncol; 2019 Aug; 144(1):11-20. PubMed ID: 31177425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 expression in meningiomas.
    Johnson MD
    J Clin Neurosci; 2018 Nov; 57():149-151. PubMed ID: 30153998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma.
    Du Z; Abedalthagafi M; Aizer AA; McHenry AR; Sun HH; Bray MA; Viramontes O; Machaidze R; Brastianos PK; Reardon DA; Dunn IF; Freeman GJ; Ligon KL; Carpenter AE; Alexander BM; Agar NY; Rodig SJ; Bradshaw EM; Santagata S
    Oncotarget; 2015 Mar; 6(7):4704-16. PubMed ID: 25609200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chrysophanol inhibits the osteoglycin/mTOR and activats NF2 signaling pathways to reduce viability and proliferation of malignant meningioma cells.
    Wang J; Lv P
    Bioengineered; 2021 Dec; 12(1):755-762. PubMed ID: 33622177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis.
    Stepanova DS; Semenova G; Kuo YM; Andrews AJ; Ammoun S; Hanemann CO; Chernoff J
    Cancer Res; 2017 Sep; 77(18):5026-5038. PubMed ID: 28729415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of PTPRJ/DEP-1 enhances NF2/Merlin-dependent meningioma development.
    Waldt N; Scharnetzki D; Kesseler C; Kirches E; Stroscher N; Böhmer FD; Mawrin C
    J Neurol Sci; 2020 Jan; 408():116553. PubMed ID: 31715329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.
    James MF; Han S; Polizzano C; Plotkin SR; Manning BD; Stemmer-Rachamimov AO; Gusella JF; Ramesh V
    Mol Cell Biol; 2009 Aug; 29(15):4250-61. PubMed ID: 19451225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the inflammatory tumor microenvironment in meningeal neoplasms.
    Berghoff AS; Kresl P; Rajky O; Widhalm G; Ricken G; Hainfellner JA; Marosi C; Birner P; Preusser M
    Clin Neuropathol; 2020; 39(6):256-262. PubMed ID: 32831157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.